Karine Lacombe

Karine Lacombe

Auto-generated profile, based on publicly available information

Karine Lacombe

Sorbonne Université, IPLESP Inserm UMR-S1136, Hôpital St Antoine, AP-HP

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2020 in Blood
Verified
Journal Article
Open access
PDF file
THThomas Hueso
Thomas Hueso
CPCécile Pouderoux
Cécile Pouderoux
HPHélène Péré
Hélène Péré
ABAnne-Lise Beaumont
Anne-Lise Beaumont
LRLaure-Anne Raillon
Laure-Anne Raillon
KLKarine Lacombe
Karine Lacombe
Anti-CD20 monoclonal antibodies are widely used for the treatment of hematological malignancies or autoimmune disease but may be responsible for a secondary humoral deficiency. In the context of COVID-19 infection, this may prevent the elicitation of a specific SARS-CoV-2 antibody response. We report a series of 17 consecutive patients with profound B-cell lymphopenia and prolonged COVID-19 symptoms, negative immunoglobulin G (IgG)-IgM SARS-CoV-2 serology, and positive RNAemia measured by digital polymerase chain reaction who were treated with 4 units of COVID-19 convalescent plasma. Within 48 hours of transfusion, all but 1 patient experienced an improvement of clinical symptoms. The inflammatory syndrome abated within a week. Only 1 patient who needed mechanical ventilation for severe COVID-19 disease died of bacterial pneumonia. SARS-CoV-2 RNAemia decreased to below the sensitivity threshold in all 9 evaluated patients. In 3 patients, virus-specific T-cell responses were analyzed using T-cell enzyme-linked immunospot assay before convalescent plasma transfusion. All showed a maintained SARS-CoV-2 T-cell response and poor cross-response to other coronaviruses. No adverse event was reported. Convalescent plasma with anti–SARS-CoV-2 antibodies appears to be a very promising approach in the context of protracted COVID-19 symptoms in patients unable to mount a specific humoral response to SARS-CoV-2.

24 February 2023 in Hepatology
Verified
Journal Article
Closed access
ONOumarou Nabi
Oumarou Nabi
NLNathanael Lapidus
Nathanael Lapidus
JBJerome Boursier
Jerome Boursier
VLVictor de Ledinghen
Victor de Ledinghen
JPJean-Michel Petit
Jean-Michel Petit
LSLawrence Serfaty
Lawrence Serfaty
Background and Aims: The severity of liver injury and clinical outcomes in lean individuals with NAFLD is a subject of debate and very few studies have been performed in the general population. The aim of this study was to compare subject characteristics and mortality between lean and nonlean NAFLD in a community setting. Approach and Results: The study population included 169,303 participants from the nationwide Constances cohort. Subjects with excessive alcohol consumption, viral hepatitis, or other liver diseases were excluded and 137,206 subjects were analyzed. The diagnosis of NAFLD and fibrosis was performed using the Fatty Liver Index and the Forns Index. The median follow-up was 3.58 years. The prevalence of NAFLD was 5.3% (95% CI: 5.2–5.4) in lean subjects, while 16.3% (95% CI: 15.7–16.8) of NAFLD subjects were lean. Despite their better metabolic profile, the prevalence of advanced fibrosis was significantly higher in lean than in nonlean NAFLD (3.7% vs. 1.7%, respectively, p < 0.01). Among NAFLD subjects and after adjustment for demographics, metabolic risk factors and lifestyle, lean status was associated with advanced fibrosis (OR=1.26, 95% CI: 1.20–1.65, p = 0.005), an increased risk of liver-related events (adjusted HR=5.84, 95% CI: 4.03–8.46), chronic kidney disease (adjusted HR=2.49, 95% CI: 1.49–4.16), and overall mortality (adjusted HR=3.01, 95% CI: 2.21–4.11). Liver-related events and overall mortality were related to the severity of fibrosis, both in lean and nonlean NAFLD subjects, whatever the usual risk factors. Conclusion: This study in a large community-based cohort confirms that NAFLD in lean subjects is more severe for fibrosis, the progression of liver disease, chronic kidney disease, and overall mortality.

1 February 2022 in Leukemia
Verified
Journal Article
Closed access
PDF file
THThomas Hueso
Thomas Hueso
AGAnne-Sophie Godron
Anne-Sophie Godron
ELEmilie Lanoy
Emilie Lanoy
JPJérôme Pacanowski
Jérôme Pacanowski
LLLaura I. Levi
Laura I. Levi
KLKarine Lacombe
Karine Lacombe

1 May 2023 in Hepatology
Verified
Journal Article
Open access
JHJessica Howell
Jessica Howell
CSChris Seaman
Chris Seaman
JWJack Wallace
Jack Wallace
YXYinzong Xiao
Yinzong Xiao
NSNick Scott
Nick Scott
MHMargaret E. Hellard
Margaret E. Hellard
Hepatitis B (HBV) is a major cause of global morbidity and mortality, and the leading cause of liver cancer worldwide. Significant advances have recently been made toward the development of a finite HBV treatment that achieves permanent loss of HBsAg and HBV DNA (so-called “HBV cure”), which could provide the means to eliminate HBV as a public health threat. However, the HBV cure is just one step toward achieving WHO HBV elimination targets by 2030, and much work must be done now to prepare for the successful implementation of the HBV cure. In this review, we describe the required steps to rapidly scale-up future HBV cure equitably. We present key actions required for successful HBV cure implementation, integrated within the World Health Organization (WHO) Global Health Sector Strategy (GHSS) 2022–2030 framework. Finally, we highlight what can be done now to progress toward the 2030 HBV elimination targets using available tools to ensure that we are preparing, but not waiting, for the cure.

8 June 2022 in Hepatology
Verified
Journal Article
Open access
CACoralie Amadou
Coralie Amadou
ONOumarou Nabi
Oumarou Nabi
LSLawrence Serfaty
Lawrence Serfaty
KLKarine Lacombe
Karine Lacombe
JBJérôme Boursier
Jérôme Boursier
MCMarie‐Aline Charles
Marie‐Aline Charles
Background and Aims: The association between birth weight (BW) and metabolic outcomes has been described since the 1980s but NAFLD has been rarely studied. This study aimed to investigate the association between BW and NAFLD occurrence in adult subjects. Approach and Results: The study population consisted of participants from the French nationwide Constances cohort from 2012 to 2019. Participants with a history of chronic viral hepatitis or excessive alcohol consumption were excluded. Noninvasive diagnosis of NAFLD and fibrosis was performed using a combination of the Fatty Liver Index (FLI) and the Forns Index. The relationship between BW and NAFLD was analyzed with a sex‐stratified logistic regression model adjusted for sociodemographic parameters, lifestyle, and birth term, whereas liver fibrosis was analyzed with a sex‐stratified linear regression model. In total, 55,034 individuals with reliable BW were included (43% men, mean age: 38 years). NAFLD (FLI ≥ 60) was present in 5530 individuals (10%). Multivariate logistic regression showed a significant U‐shaped relationship between BW and NAFLD, with no significant interaction with sex. A significant and slightly decreasing association was found between BW and Forns Index (β = −0.05; p = 0.04). Premature birth (OR, 1.23; 95% CI, 1.03–1.48 for birth between 33 and 37 weeks versus ≥ 37 weeks) was associated with NAFLD, with a significant direct effect of premature birth, and without an indirect effect of low BW in mediation analysis. Forns Index was not significantly higher in participants with preterm birth compared to full‐term birth. Conclusions: This large prospective adult‐based cohort confirms the relationship between BW and NAFLD occurrence.

12 March 2020 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
ECEvan Cunningham
Evan Cunningham
BHBehzad Hajarizadeh
Behzad Hajarizadeh
JAJanaki Amin
Janaki Amin
MHMargaret Hellard
Margaret Hellard
JBJulie Bruneau
Julie Bruneau
JGJason Grebely
Jason Grebely
Background: The aim of this analysis was to calculate the incidence of hepatitis C virus (HCV) reinfection and associated factors among 2 clinical trials of HCV direct-acting antiviral treatment in people with recent injecting drug use or currently receiving opioid agonist therapy (OAT). Methods: Participants who achieved an end-of-treatment response in 2 clinical trials of people with recent injecting drug use or currently receiving OAT (SIMPLIFY and D3FEAT) enrolled between March 2016 and February 2017 in 8 countries were assessed for HCV reinfection, confirmed by viral sequencing. Incidence was calculated using person-time of observation and associated factors were assessed using Cox proportional hazard models. Results: Seventy-three percent of the population at risk of reinfection (n = 177; median age, 48 years; 73% male) reported ongoing injecting drug use. Total follow-up time at risk was 254 person-years (median, 1.8 years; range, 0.2–2.8 years). Eight cases of reinfection were confirmed for an incidence of 3.1/100 person-years (95% confidence interval [CI], 1.6–6.3) overall and 17.9/100 person-years (95% CI, 5.8–55.6) among those who reported sharing needles/syringes. Younger age and needle/syringe sharing were associated with HCV reinfection. Conclusions: These data demonstrate the need for ongoing monitoring and improved strategies to prevent HCV reinfection following successful treatment among people with ongoing injecting drug use to achieve HCV elimination. Clinical Trials Registration: NCT02336139 and NCT02498015.